The Psilocybin Pioneers
A Swiss chemist discovered the molecule by accident in 1943, a Harvard psychologist introduced it to the counterculture and helped ban it from research for thirty years, and a Johns Hopkins pharmacologist spent twenty-five years earning it back.
April 16, 1943. Albert Hofmann is at his bench at Sandoz Laboratories in Basel, Switzerland, resynthesizing a compound he first made five years earlier and then set aside. LSD-25, the twenty-fifth in a series of lysergic acid derivatives he had been systematically studying for cardiac applications. The animal tests had shown nothing remarkable. He filed it away.
He does not know why he came back to it. He said, more than once, that he could not fully explain the impulse. Some chemist’s intuition that the compound had not finished with him.
Within an hour of handling it, he feels dizzy. He notes unusual restlessness. He goes home, lies down, and closes his eyes. What follows is a two-hour stream of extraordinarily vivid imagery, kaleidoscopic colors, shapes that dissolve and recombine. Then it fades.
He suspects absorption through the skin. Three days later, on April 19, he intentionally ingests 250 micrograms, a quantity he assumes is modest. He is wrong by roughly tenfold. Within an hour, the room begins to dissolve. He asks his laboratory assistant to accompany him home. Wartime restrictions have banned automobile traffic. They ride bicycles. This is the detail that fixed itself in cultural memory: the most consequential bicycle ride in the history of pharmacology, a Swiss chemist coming apart at the seams, pedaling through the streets of Basel.
He survived the ride. He survived the night, though barely. He also survived sixty more years, during which he would argue, with precision and patience, that what happened to him on that bicycle was not a malfunction but a signal.
Albert Hofmann was born in 1906 in Baden, Switzerland. He joined Sandoz Laboratories in 1929 and spent his career extracting and studying the alkaloids of ergot fungus, the parasitic organism that grows on rye and had caused epidemics of mass poisoning in medieval Europe. Out of that ancient pathogen, he was trying to find useful medicine. He succeeded in several directions before LSD.
After Bicycle Day, the compound could not be quietly shelved. Sandoz distributed it to researchers under the trade name Delysid. Psychiatric clinics across Europe and North America began studying it. Before the counterculture discovered it, LSD had a growing clinical literature. Suggested applications were specific and measurable: model psychoses for studying schizophrenia, an adjunct to psychotherapy for helping patients access unconscious material. Thousands of papers were published. The field was moving.
Then, in 1958, a different compound arrived at Hofmann’s bench.
R. Gordon Wasson, a New York banker and mycologist, had traveled to Oaxaca, Mexico, in 1955 and witnessed the mushroom ceremonies of a Mazatec healer named Maria Sabina. He consumed the mushrooms. His account appeared in Life Magazine in 1957 under the headline “Seeking the Magic Mushroom.” He brought specimens back and delivered them to Sandoz.
Hofmann was tasked with identifying the active compound. In 1958, he isolated it. He characterized it. He synthesized it. He named it psilocybin. He named the companion compound psilocin. The results appeared in Helvetica Chimica Acta, written with the economy and precision that characterized everything he produced.
That act, the isolation and synthesis of psilocybin from Psilocybe mexicana, was the chemical foundation of every clinical trial that followed over the next seventy years. To study a molecule rigorously, you need it in pure, measurable form. Hofmann provided that. Without his 1958 work, there is no research protocol. There is no Roland Griffiths. There is no FDA breakthrough therapy designation for psilocybin. The entire modern scientific inquiry into psilocybin begins at Hofmann’s bench in Basel.
He retired from Sandoz in 1971 and spent the rest of his life writing and speaking about what he had found. He was not a counterculture figure in any sense that would have been comfortable to him. He was a precise, conservative Swiss chemist who found the compound’s association with the 1960s recreational scene genuinely distressing, not because he disapproved of the experience but because he believed context was everything. Set and setting, a phrase that was common in his circles long before Timothy Leary formalized it. The environment, the intention, the preparation. These were not optional refinements. They were the difference between a healing and a crisis.
His book, published in 1979, was called “LSD: My Problem Child.” He chose the title deliberately. Not because he regretted the discovery but because he mourned what had happened to it: a promising compound with real therapeutic potential had become a symbol of everything that frightened the mainstream, a political lightning rod that would shut down twenty years of research overnight. He watched it happen. He was seventy-three when he wrote about it.
He died in April 2008, at age 102, in Burg im Leimental, Switzerland, five years before the research he made possible would produce results he had spent his life hoping for.
Timothy Leary arrived at Harvard in 1959 as a lecturer in clinical psychology. He was thirty-eight years old, a trained researcher with a background in personality testing and group therapy, and a specific and unusual willingness to make himself the subject of whatever he studied. A colleague returned from Mexico in 1960 with psilocybin mushrooms and offered Leary some. Leary ate them by a swimming pool in Cuernavaca and had what he later described as the most profound experience of his life. He was a different person by the time he came back to Cambridge.
He started the Harvard Psilocybin Project with his colleague Richard Alpert. They obtained pharmaceutical psilocybin from Sandoz through legal channels and began systematic study. The work was real. Walter Pahnke’s doctoral dissertation, supervised under Leary’s group, administered psilocybin to seminary students in Marsh Chapel on Good Friday in 1962. A meaningful proportion reported experiences indistinguishable from classical mystical states: a sense of unity, transcendence of time and space, ineffability, something they described as sacred. A twenty-five-year follow-up conducted by Rick Doblin in 1989 found the effects had persisted. That study is still cited in contemporary psilocybin research.
Leary and Alpert, working with Ralph Metzner, also formalized the concept of set and setting. The internal state of the person taking the compound and the physical and social environment surrounding the experience were the primary determinants of what happened. This was not a casual observation. Every clinical trial in psilocybin research over the next sixty years would validate it. Leary got that right.
The project was also unraveling. Critics raised concerns about methodology, about the involvement of undergraduate students, about the blurring of researcher and subject. In 1963, Harvard dismissed both Leary and Alpert. The official reason was conduct violations. The real reason was that the project had already moved past the boundaries of credible academic research.
After Harvard, Leary moved to Millbrook, a sixty-four-room estate in New York funded by a wealthy patron, where he spent several years hosting an intentional community and continuing to consume and advocate for psychedelics publicly. The research framework fell away. What replaced it was prophecy.
“Turn on, tune in, drop out.” The phrase premiered at the Human Be-In in Golden Gate Park in January 1967. Leary was on a stage in front of tens of thousands of people. What he was describing was a complete refusal of mainstream American institutional life, an invitation to the counterculture to treat psychedelic experience as a political act. The phrase was exactly what his opponents needed.
Richard Nixon, in a 1971 statement, called Leary “the most dangerous man in America.” The administration did not treat that characterization as rhetoric. The political pressure generated by the association between psychedelics, counterculture radicalism, and social upheaval produced something specific and durable: the Controlled Substances Act of 1970 classified LSD and psilocybin as Schedule I controlled substances, placing them in the category of drugs with no accepted medical use and high potential for abuse. Research protocols were not preserved. Clinical trials were not transitioned. The entire existing literature, hundreds of papers, thousands of patients, was frozen in place. The FDA halted new studies. The DEA controlled supply. For thirty years, the regulatory burden of conducting Schedule I research in humans was designed to be prohibitive, and it was.
Leary was arrested in 1970 for marijuana possession, sentenced to ten years, escaped with assistance from the Weather Underground, fled internationally, was recaptured in Kabul in 1973, served additional time, and was released in 1976. He spent his remaining years as a lecturer and minor celebrity, enthusiastic about computers and the emerging internet. He died of prostate cancer in Beverly Hills in May 1996.
The research moratorium he helped create outlasted him by three years.
The thing that is hard to account for in the Leary story is that he was not wrong. The experiences he was describing were real. The therapeutic potential he was claiming was real. The research would eventually confirm all of it. The cruelty is that he was right about the substance and catastrophically wrong about the manner and timing of introduction. A society that had no cultural container for direct encounters with radically altered consciousness, that was already frightened by the pace of social change, did not respond to “turn on, tune in, drop out” by calmly designing clinical trials. It responded by scheduling the compounds.
He handed his opponents everything they needed. He knew he was doing it. He kept going. That is either courage or recklessness. In 1996, when he died, the question had not been answered, because the field was still frozen.
In the late 1990s, a behavioral pharmacologist at Johns Hopkins named Roland Griffiths began navigating the regulatory process to conduct human research on psilocybin.
He was not from the counterculture. He had spent more than thirty years studying the behavioral pharmacology of caffeine, sedatives, and drug dependence. He was a scientist in the precise institutional sense: someone who had built a career within academic medicine, published in peer-reviewed journals, designed controlled studies, worked within IRBs. He was, in every biographical dimension, the opposite of Timothy Leary.
He was also a long-term meditation practitioner. His personal experience with contemplative states had made him curious about psilocybin at the level of consciousness. That curiosity was not an excuse to bypass the science. It was a reason to do it carefully.
Obtaining DEA Schedule I researcher authorization to study psilocybin in human subjects required years. Not months. Years. The regulatory infrastructure built after the Controlled Substances Act was not designed to accommodate researchers with sincere questions. Griffiths navigated it anyway.
In 2006, Psychopharmacology published “Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance.” The paper described a double-blind study of thirty-six healthy volunteers with no prior hallucinogen experience. In sessions where they received psilocybin rather than an active placebo, a third rated the experience as the single most spiritually significant of their lives. Two-thirds rated it in the top five. At a two-month follow-up, seventy-nine percent reported moderately or greatly increased well-being. The design was rigorous. The effect sizes were large. The publication venue mattered: this was not fringe science. It was peer-reviewed psychiatric research at one of the most credible medical schools in the country.
The fourteen-month follow-up, published in 2008, showed the effects were not fading. Well-being, life satisfaction, openness to experience: all persisted. The finding on openness was unusual enough to warrant attention on its own. Changes in personality in adults are generally considered slow and difficult to produce. A single psilocybin session was producing persistent, measurable increases in openness more than a year later.
Matthew Johnson, who joined Hopkins as a postdoctoral researcher and stayed as faculty, became Griffiths’s primary collaborator. Mary Cosimano, who had worked as a social worker before joining the lab, became the center’s master guide and session facilitator. A smoking cessation study published in 2014 showed eighty percent abstinence at six months in a small pilot, a rate that compared favorably to every existing pharmacological intervention in the cessation literature.
In 2016, in partnership with researchers at NYU, the Hopkins group published results from a study of cancer patients with life-threatening diagnoses and significant depression and anxiety. Single psilocybin sessions produced reductions in depression and anxiety scores that were still present at six months. Eighty percent of participants showed clinically significant reductions. The effect sizes were the largest seen in psychiatric research in decades. One participant said her cancer was not the most important thing that had ever happened to her.
In 2019, Johns Hopkins Center for Psychedelic and Consciousness Research opened, the first such center at a major American academic institution since the moratorium began. Griffiths was founding director. The funding came from private philanthropy, including a significant contribution from Tim Ferriss, because federal research funding for Schedule I compounds remained difficult to obtain.
In early 2023, Griffiths was diagnosed with stage IV colon cancer.
He continued working. He underwent psilocybin therapy himself and spoke publicly about the experience. His account was careful and precise, the account of a scientist reporting an observation. He described a deepened equanimity about death. He said he was not afraid. He published on major depressive disorder. He continued as director. He died on October 16, 2023.
He spent twenty-five years methodically rebuilding what Leary had burned down in five. That accounting is accurate, and it is also incomplete.
Griffiths did not simply reverse the damage by being more careful. He built something harder: an institutional structure at one of the most credible medical schools in the world, with methodology rigorous enough that the FDA eventually cited his results in granting psilocybin breakthrough therapy designation for major depressive disorder. The researchers now running clinical trials for depression, addiction, and end-of-life anxiety are building on the evidence base he assembled.
He also did something Leary was constitutionally incapable of doing. He made the work boring. Not accidentally but deliberately, methodically, institutionally boring. No manifestos. No communes. No bicycle rides into the sunset. A double-blind placebo-controlled study. A peer-reviewed journal. A DEA license. A fourteen-month follow-up. He applied the full methodological apparatus of academic medicine to one of the most extraordinary phenomena in pharmacology, precisely so that academic medicine could not dismiss it.
What the three of them together represent is a sixty-year arc that the current psychedelic renaissance inherits whether it knows it or not.
Hofmann gave the field its chemistry. The isolation of psilocybin in 1958 was not romantic. It was technical, precise, and reproducible. You cannot run a clinical trial on a compound you cannot measure. You cannot study dose-response relationships without purity and consistency. Hofmann’s synthesis was the prerequisite: the thing that had to be done before anything else was possible.
Leary gave the field its notoriety and then its thirty-year exile. The notoriety introduced a compound with genuine therapeutic potential to millions of people who would never have encountered it through clinical channels. The exile cost those same people thirty years of research that was not done, treatments that were not developed, suffering that might have been addressed. Leary’s bet was that the truth about these substances was urgent and self-evidently important enough that the culture would catch up. It was not an unreasonable bet. It was catastrophically mistimed.
Griffiths gave the field its credibility, and in the end, himself. The credibility came from the methodology, from the decision to work within the system rather than around it, from understanding that the only instrument capable of reversing the Leary damage was the kind of evidence that people who created that damage would have to take seriously. The gift of himself was less planned but no less real. When the founding director of the most important psilocybin research center in the world underwent psilocybin therapy for terminal cancer and reported finding it genuinely useful, that was a different kind of data: the kind that does not appear in a journal, the kind that answers a question clinical trials cannot ask.
All three were right. All three paid costs. The discoveries were made but took eighty years to reach their potential. The urgency was real but the approach nearly destroyed the field. The methodology worked but consumed another thirty years.
The current moment, in which psilocybin research is conducted openly at major institutions, in which FDA designations are advancing, in which clinical trials are recruiting patients for depression and addiction and end-of-life distress, is the accumulated inheritance of all three. Not just the science. The science plus the cautionary tale. The chemistry plus the wreckage. The rigor plus the memory of what happens when you treat a powerful compound like a manifesto instead of a molecule.
Hofmann, Leary, and Griffiths each made a bet. Hofmann bet that careful discovery and open sharing would produce something useful. Leary bet that the truth was urgent enough to override every institutional constraint. Griffiths bet that institutional constraint was the only instrument capable of making the truth legible.
The arc from the bicycle in Basel to the bed in Baltimore where a dying scientist reported finding peace is not a story about drugs. It is a story about how humans encounter things that exceed their existing categories, and what they are willing to risk to find out what those things are worth.